University of Georgia College of Pharmacy, Department of Clinical and Administrative Pharmacy, 914 New Bailie Street, HM-118, Augusta, GA 30912, United States; Augusta University Medical Center, Department of Pharmacy, 1120 15(th) Street, Augusta, GA 30912, United States.
University of Georgia College of Pharmacy, Department of Clinical and Administrative Pharmacy, 914 New Bailie Street, HM-118, Augusta, GA 30912, United States; Augusta University Medical Center, Department of Pharmacy, 1120 15(th) Street, Augusta, GA 30912, United States.
Epilepsy Behav. 2022 Sep;134:108833. doi: 10.1016/j.yebeh.2022.108833. Epub 2022 Jul 13.
The appropriate loading dose strategy for phenytoin/fosphenytoin in overweight patients is unknown. A small pharmacokinetic study indicated that overweight patients have a higher volume of distribution and potentially would benefit from using adjusted body weight (AdjBW) instead of actual body weight (ABW) to calculate the loading dose. The purpose of this study was to determine the optimal loading dose strategy of phenytoin in patients whose ABW is greater than 120% of their ideal body weight (IBW) using either ABW or AdjBW for calculation of the loading dose.
This was a single center, retrospective study which included patients who received a loading dose of phenytoin of at least 10 mg/kg based on ABW, had a phenytoin level drawn <6 h after the end of the dose, and weighed ≥120% of their IBW. Patients were excluded if they received intramuscular phenytoin or fosphenytoin or were prescribed phenytoin prior to the loading dose. Patients were divided into two groups, those who were dosed using their AdjBW versus those dosed using ABW. The primary outcome was achievement of therapeutic phenytoin level of 10-20 mcg/mL. Secondary outcomes included achievement of a subtherapeutic or supratherapeutic level.
A total of 195 patients (128 in AdjBW group and 67 in ABW group) met criteria for inclusion. Patients in the AdjBW group weighed more (96.2 kg vs. 91.2 kg, p = 0.04) and received a lower dose in milligrams (1364 vs. 1760, p < 0.0001) and in mg/kg of ABW (14.2 vs. 19.3, p < 0.0001). The primary outcome was achieved in 74% of patients in the AdjBW group and 57% of patients in the ABW group (p = 0.02). Patients in the ABW group were more likely to have a supratherapeutic level (43% vs. 22%, p = 0.003), although adverse reactions did not differ between the groups.
Patients weighing >120% of their IBW (average body mass index 33.5 kg/m) who received a 20 mg/kg loading dose based on AdjBW were more likely to achieve a therapeutic phenytoin concentration compared to those dosed based on ABW. Further research is needed to correlate this finding with clinical outcomes, such as resolution of status epilepticus.
对于超重患者,苯妥英/磷苯妥英的合适负荷剂量策略尚不清楚。一项小型药代动力学研究表明,超重患者的分布容积更高,可能受益于使用调整后的体重(AdjBW)而不是实际体重(ABW)来计算负荷剂量。本研究的目的是确定使用 ABW 或 AdjBW 计算负荷剂量时,ABW 超过理想体重(IBW)120%的患者的苯妥英最佳负荷剂量策略。
这是一项单中心回顾性研究,纳入了接受 ABW 计算的至少 10mg/kg 负荷剂量的患者,在剂量结束后<6 小时内抽取了苯妥英水平,并称重超过 IBW 的 120%。如果患者接受肌肉内苯妥英或磷苯妥英或在负荷剂量前开了苯妥英,则排除在外。患者分为两组,一组使用 AdjBW 给药,另一组使用 ABW 给药。主要结局是达到 10-20mcg/mL 的治疗性苯妥英水平。次要结局包括达到亚治疗或超治疗水平。
共有 195 名患者(AdjBW 组 128 名,ABW 组 67 名)符合纳入标准。AdjBW 组患者体重更重(96.2kg 比 91.2kg,p=0.04),接受的剂量更低(毫克数 1364 比 1760,p<0.0001),ABW 毫克/千克剂量也更低(14.2 比 19.3,p<0.0001)。AdjBW 组的主要结局发生率为 74%,ABW 组为 57%(p=0.02)。ABW 组患者更有可能出现超治疗水平(43%比 22%,p=0.003),尽管两组的不良反应没有差异。
体重超过 IBW 120%(平均体重指数 33.5kg/m)的患者接受基于 AdjBW 的 20mg/kg 负荷剂量时,与基于 ABW 给药的患者相比,更有可能达到治疗性苯妥英浓度。需要进一步研究将这一发现与临床结局相关联,如癫痫持续状态的缓解。